Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 251-156-3 | CAS number: 32687-78-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 31 Jan 1983 - 25 Jan 1984
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 984
- Report date:
- 1984
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- (adopted 1981)
- Deviations:
- no
- GLP compliance:
- yes
- Remarks:
- Ciba-Geigy Ltd., Basle/Switzerland, GU2 Toxicology
- Limit test:
- no
Test material
- Reference substance name:
- 2',3-bis[[3-[3,5-di-tert-butyl-4-hydroxyphenyl]propionyl]]propionohydrazide
- EC Number:
- 251-156-3
- EC Name:
- 2',3-bis[[3-[3,5-di-tert-butyl-4-hydroxyphenyl]propionyl]]propionohydrazide
- Cas Number:
- 32687-78-8
- Molecular formula:
- C34H52N2O4
- IUPAC Name:
- 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-N'-[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoyl]propanehydrazide
- Details on test material:
- - Physical state: solid
- Analytical purity: 100% (spectrophotometrically)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: F3-hybrid of RII 1/Tif x RII 2/Tif
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Tif: RAIf (SPF) rats from Animal Production, CIBA-GEIGY LTD., 4332 Stein, Switzerland
- Age at study initiation: 6 weeks
- Weight at study initiation: 190-195 g (males), 173-175 g (females)
- Housing: 5 animals per cage (Makrolon Cage Type 4)
- Diet: Pelleted, certified standard diet Nafag No. 890 Tox, ad libitum
- Water: Tap water, ad libitum
- Acclimation period: 10 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22+/-2
- Humidity (%): 55+/-10
- Air changes (per hr): 16-20
- Photoperiod: 12 hrs dark / 12 hrs light
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test substance was weighed on a calibrated Mettler balance. The pulverised food was then homogeneously mixed with the appropriate concentrations of the compound and 30% water was added before pelleting to ensure the necessary pellet quality. The pellets were subsequently air dried. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Prior to the initiation of the study, pretest feed samples were analysed for concentration of test material. The same was undertaken periodically with the food batches applied during the test. The analysis were carried out in the Central Analytical Laboratories of CIBA-GEIGY LTD., Basle/Switzerland.
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- continuous over 90 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 400 ppm
- Remarks:
- Corresponding to 25 mg/kg bw in males and 27 mg/kg bw in females.
- Dose / conc.:
- 2 000 ppm
- Remarks:
- Corresponding to 123 mg/kg bw in males and 127 mg/kg bw in females.
- Dose / conc.:
- 10 000 ppm
- Remarks:
- Corresponding to 624 mg/kg bw in males and 667 mg/kg bw in females.
- No. of animals per sex per dose:
- 20
- Control animals:
- yes, plain diet
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily on working days (mortality); daily (symptoms)
BODY WEIGHT: Yes
- Time schedule for examinations: weekly (midweek)
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- mean food conversion was calculated based on weekly food consumption and midweek body weight.
WATER CONSUMPTION: Yes
- Time schedule for examinations: monthly (week 3, 7, 11)
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: at the beginning and towards the end of the treatment period (day -6 and day 86 of test)
- Dose groups that were examined: in control animals and in treated animals of the highest dose level
HEARING TEST: Yes
- Time schedule for examinations: at the beginning and towards the end of the treatment period (day -6 and day 86 of test)
- Dose groups that were examined: in control animals and in treated animals of the highest dose level
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the end of the treatment period
- Anaesthetic used for blood collection: Yes (Ether anaesthesia)
- Animals fasted: Yes (20 hours before collection of blood)
- How many animals: 20 per sex and per group
- Following parameters were examined: RBC, HCT, Hb, MCV, PCV, MCH, PLT, WBC, Differential blood count, Reticulocytes, Prothrombin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the end of the treatment period
- Animals fasted: Yes (20 hours before collection of blood)
- How many animals: 20 per sex and per group
- Following parameters were examined: Glucose, Urea, Total Protein, Creatinine, Albumine, Globuline, A/G ratio, Sodium, Potassium, Chloride, Calcium, Phosphorus inorganic, GPT, GOT, AP, Total Cholesterol
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
At the end of the test period all control and test animals were bled under ether anaesthesia and subjected to detailed autopsy. Liver, adrenals, brain, thymus, heart, kidneys and gonads were weighed. The following organs and tissues were preserved in 10% neutral formalin:
skin, mammary area, spleen, mesenteric lymph node, axillary lymph node, sternum with bone marrow, femur with joint, skeletal muscle, trachea, lung, heart, aorta, submandibular salivary gland, liver, pancreas, oesophagus, stomach, small intestine, large intestine, kidney, urinary bladder, prostate, seminal vesicle, testis, epididymis, uterus, ovary, pituitary gland, adrenal gland, thyroid with parathyroid gland, thymus, peripheral nerve, brain, spinal cord, eye with optic nerve, orbital gland, extraorbital lacrimal gland, organs and tissues showing macroscopical changes.
Complete autopsy with tissue preservation was performed also in all animals which died during the test period.
HISTOPATHOLOGY: Yes
After the fixation organ samples from each control and test rat were taken, embedded in paraplast, sectioned at 3-5 microns, stained with haematoxylin and eosin and subjected to microscopical examination. - Statistics:
- For each time point and parameter a uni-variate statistical analysis was conducted. Due to the routine manner of the analysis system, parameter free methods were applied. Each treated group was compared to the control group in respect of dispersion and displacement (1). In addition a trend test (2) was applied considering all groups. Statistical analysis is performed to draw attention to distinct values. A statistically significant difference between two values does not necessarily imply biological relevance of that deviation and is not conclusive for a treatment related effect. Hence, the responsible scientist may not comment on statistically significant values lying within the physiological range and on the other hand may comment on statistically not significant values, which differ substantially from the expected normal values.
(1) Y. Lepage, Biometrika (1971) 58: pp. 213-217.
(2) H. R. Jonckheere, Biometrika (1954) 41: pp. 133-145
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- No clinical symptoms and no signs of local and/or systemic toxicity were observed.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- No death which was related to the administration of the test compound occurred in the course of the study. One animal (male no 55, group 3) died during blood withdrawal at the end of the treatment period.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The mean body weight gain of all treated male and female groups was similar to that of the respective control groups, except a marginally lower weight increase in treated male group 4 (10 000 ppm), which however was not significant and within a range of 10 % of the control value.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- The mean food consumption of all treated male and female groups was similar to that of the respective control groups. Specific food consumption in relation to body weight in treated animals was similar to that of the respective control groups.
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- The mean water consumption of all treated male and female groups was similar to that of the respective control groups.
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthalmic inspections and hearing examinations performed before and towards the end of the administration period revealed no evidence of a reaction to the treatment.
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Hematological investigations at week 14 showed a minimal increase in numbers of thrombocytes in females of group 4 (10000 ppm).
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Blood chemistry investigations revealed slightly lower sodium concentrations and higher concentrations of inorganic phosphorus in the females of group 4 (10000 ppm). The total protein concentration and the albumin concentration were noted to be marginally lower in the females of group 4 (10000 ppm). The globulin concentration of this group was slightly increased. The toxicological significance of these findings is doubtful.
Other parameters examined in hematology and blood chemistry achieving a level of statistical significance in their difference from control values were considered to have arisen fortuitously. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A slight, but significant decrease of the liver weight was observed in treated male rats of groups 3 and 4 (2000 and 10000 ppm). A slight decrease of testes weight was noted in treated male group 4 (10000 ppm). Additional statistically significant differences in organ weights between treated and control groups were noted. Incidental, however statistically significant differences in organ weights between treated and control groups were noted. Since no systematic pattern emerged, these differences were attributed to spontaneous variation rather than to the treatment.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No macroscopical changes were observed that were considered to be due to the administration of the test compound.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Apart from an increasing incidence of nonspecific, minimal inflammatory cell infiltration in the liver in male animals of treated groups 3 and 4 (2000 and 10000 ppm) no microscopical changes were observed that were considered to be due to the administration of the test compound.
- Histopathological findings: neoplastic:
- not examined
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 400 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: At the next higher dose level, slight decrease in the liver weight and an incidence of non-specific minimal inflammatory cell infiltration were recorded.
- Dose descriptor:
- NOAEL
- Effect level:
- 624 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: no adverse effects at this dose level
- Dose descriptor:
- NOAEL
- Effect level:
- 667 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: no adverse effects at this dose level
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1: Mean organ weights (g) and ratios (as a percentage of body- and brain weight) of male animals in test week 14.
Organs |
Dose (ppm in food) |
Trend |
|||
|
0 |
400 |
2000 |
10000 |
|
Body |
457 |
460 |
450 |
435 |
|
Brain |
2.40 |
2.41 |
2.45 |
2.44 |
|
Brain/body |
0.53 |
0.53 |
0.55 |
0.56 |
|
Heart |
1.37 |
1.29 |
1.28 |
1.31 |
|
Heart/body |
0.3 |
0.28* |
0.285 |
0.31 |
|
Heart/brain |
56.99 |
53.50* |
52.37* |
53.56 |
|
Liver |
14.97 |
16.11 |
13.92 |
12.36* |
X |
Liver/body |
3.27 |
3.51* |
3.10* |
2.85* |
X |
Liver/brain |
624.7 |
670.3 |
570.9* |
506.8* |
X |
Kidneys |
2.79 |
2.79 |
2.80 |
2.74 |
|
Kidneys/body |
0.61 |
0.61 |
0.62 |
0.63 |
|
Kidneys/brain |
116.1 |
115.9 |
114.3 |
112.4 |
|
Adrenals |
0.068 |
0.070 |
0.066 |
0.068 |
|
Adrenals/body |
0.0148 |
0.0152 |
0.0147 |
0.0157 |
|
Adrenals/brain |
2.83 |
2.91 |
2.70 |
2.78 |
|
Thymus |
0.41 |
0.43 |
0.44 |
0.46 |
|
Thymus/body |
0.090 |
0.093 |
0.098 |
0.105 |
|
Thymus/brain |
17.10 |
17.83 |
17.96 |
18.72 |
|
Gonads |
3.82 |
3.53 |
3.62 |
3.43* |
X |
Gonads/body |
0.84 |
0.78 |
0.81 |
0.79 |
|
Gonads/brain |
159.2 |
147.2 |
148.3* |
140.6* |
X |
*: Significant difference (location and/or dispersion) between control group and test group (sign. l. = 0.05)
X: Significant negative trend from control to highest dosage group (sign. L. = 0.1)
Table 2: Mean
organ weights (g) and ratios (as a percentage of body- and brain weight) of
female animals in test week 14.
Organs |
Dose (ppm in food) |
Trend |
|||
|
0 |
400 |
2000 |
10000 |
|
Body |
302.3 |
312.4 |
315.6 |
298.7 |
|
Brain |
2.33 |
2.33 |
2.36 |
2.32 |
|
Brain/body |
0.774 |
0.749 |
0.757 |
0.780 |
|
Heart |
0.972 |
0.974 |
0.970 |
0.916 |
|
Heart/body |
0.322 |
0.313* |
0.310* |
0.308 |
|
Heart/brain |
41.77 |
41.99 |
41.29 |
39.66 |
|
Liver |
10.74 |
10.60 |
10.33 |
10.31 |
|
Liver/body |
3.56 |
3.40 |
3.29* |
3.45 |
|
Liver/brain |
461.2 |
455.4 |
438.5 |
446.1 |
|
Kidneys |
2.06 |
1.98 |
2.04 |
2.08 |
|
Kidneys/body |
0.69 |
0.64* |
0.65 |
0.70 |
|
Kidneys/brain |
88.6 |
85.3 |
86.5 |
89.8 |
|
Adrenals |
0.093 |
0.087 |
0.094 |
0.088 |
|
Adrenals/body |
0.0308 |
0.0282 |
0.0300 |
0.0298 |
|
Adrenals/brain |
3.99 |
3.76 |
4.00 |
3.82 |
|
Thymus |
0.303 |
0.315 |
0.312 |
0.286 |
|
Thymus/body |
0.101 |
0.101 |
0.099 |
0.096 |
|
Thymus/brain |
13.08 |
13.59 |
13.33 |
12.38 |
|
Gonads |
0.174 |
0.190 |
0.175 |
0.177 |
|
Gonads/body |
0.058 |
0.062 |
0.056 |
0.060 |
|
Gonads/brain |
7.49 |
8.20 |
7.42 |
7.66 |
|
*: Significant difference (location and/or dispersion) between control group and test group (sign. l. = 0.05)
Table 3: Summary of macroscopical findings in female and male animals.
|
Dose (ppm in food) |
||||||||||
|
0 |
400 |
2000 |
10000 |
|||||||
|
m |
f |
m |
f |
m |
f |
m |
f |
|||
Animals examined macroscopically |
20 |
20 |
20 |
20 |
20 |
20 |
20 |
20 |
|||
Abdominal cavity nodule (<0.5 cm) |
|
|
1 |
|
|
|
|
|
|||
Body as a whole, no changes observed |
20 |
19 |
18 |
19 |
19 |
20 |
18 |
18 |
|||
Brain Damaged during autopsy malformation |
|
1 |
1 |
|
|
|
|
|
|||
Kidney Fibrinous adhesion Small |
|
|
|
|
|
|
1 |
1
1 |
|||
Ovary Cyst (<1 cm) |
|
|
|
1 |
|
|
|
|
|||
Spleen Fibrinous adhesion small |
|
|
|
|
|
|
|
1
1 |
|||
Testis Small bilateral |
|
|
|
|
1 |
|
1 |
|
|||
Thymus Haemorrhage |
|
1 |
|
|
|
|
|
|
|||
Uterus Dilatation |
|
|
|
|
|
|
|
1 |
Applicant's summary and conclusion
- Executive summary:
In an oral subchronic study Tif : RAIf (SPF) rats (20 per sex and dose group) were dosed for 90 days with 400, 2000 and 10000 ppm test substance added to the diet (calculated mean daily intake: 25, 123 and 624 mg/kg bw for males and 27, 127 and 667 mg/kg bw for females). No deaths related to the administration of the test compound occurred in the course of the study. No clinical symptoms and no signs of local and/or systemic toxicity were observed. The mean body weight gain of all treated male and female groups was similar to that of the respective control groups, except a marginally lower weight increase in treated male group 4 (10000 ppm), which however was not significant and within the range of 10 % of the control value. The mean food consumption of all treated male and female groups was similar to that of the respective control groups. Hematological investigations at week 14 showed a minimal increase in numbers of thrombocytes in females of group 4 (10000 ppm). Blood chemistry investigations revealed slightly lower sodium concentrations and higher concentrations of inorganic phosphorus in the females of group 4 (10000 ppm). The total protein concentration and the albumin concentration were noted to be marginally lower in the females of group 4 (10000 ppm). The globulin concentration of this group was slightly increased. The toxicological significance of these findings is doubtful. Other parameters examined in hematology and blood chemistry achieving a level of statistical significance in their difference from control values were considered to have arisen fortuitously. A slight, but significant decrease of the liver weight was observed in treated male rats of groups 3 and 4 (2000 and 10000 ppm). A slight decrease of testes weight was noted in treated male group 4 (10000 ppm). Additional statistically significant differences in organ weights between treated and control groups were noted. Since no systematic pattern emerged, these differences were attributed to spontaneous variation rather than to the treatment. Apart from an increasing incidence of nonspecific, minimal inflammatory cell infiltration in the liver in male animals of treated groups 3 and 4 (2000 and 10000 ppm) no macroscopical or microscopical changes were observed that were considered to be due to the administration of the test compound. In conclusion a NOEL of 25 (males) and 27 (females) mg/kg bw per day was derived, based on increased incidence of inflammatory cell infiltration in the liver of mainly male animals. Since no specific local or systemic effects have been observed up to the highest dose tested, the NOAEL was raised to 624 (males) and 667 mg/kg bw (females).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)